Back to search

The FDA Should Eliminate the Ambiguities in the Current BCS Biowaiver Guidance and Make Public the Drugs for Which BCS Biowaivers Have Been Granted

Data up to Jan 2025

Published2010
Citations39
References8

Total Citations Per Year

Abstract

The FDA Should Eliminate the Ambiguities in the Current BCS Biowaiver Guidance and Make… (2010) – Clinical Pharmacology & Therapeutics | Metascience Observatory Explorer